The introductory statement of When and In Whom to Initiate Therapy has been revised to reiterate that treatment will benefit almost all patients in all stages of chronic infection and that urgent initiation of therapy is needed in patients with certain conditions.

The newest section of the AASLD/IDSA/IAS–USA hepatitis C Guidance, Management of Acute HCV Infection, is now available. Click here to access this section.

Updated information on drug interactions between simeprevir and certain immunosuppressant drugs has been added based on the manufacturer’s revised product prescribing information. For more information see Unique Patient Populations.

The newest section of the AASLD/IDSA/IAS-USA hepatitis C Guidance, Monitoring Patients Who Are Starting HCV Treatment, Are On Treatment, Or Have Completed Therapy, is now available. Click here to access this section.

Simeprevir concentration is increased by approximately 6-fold when coadministered with cyclosporine (in combination with daclatasvir [an investigational drug] and RBV). Coadministration of simeprevir with cyclosporine is not recommended. For more information see Unique Patient Populations.

We are pleased to introduce the newest section of the Guidance, When and in Whom to Initiate HCV Therapy. Successful hepatitis C treatment results in sustained virologic response (SVR), which is tantamount to virologic cure; virologic cure is expected to benefit chronically infected persons.

View Official Press Release: When and In Whom to Initiate HCV Therapy Now Available at www.HCVguidelines.org

How to cite the Guidance in papers

The website as a whole.
AASLD-IDSA. Recommendations for testing, managing, and treating hepatitis C. https://www.hcvguidelines.org. $$$Insert date accessed here$$$.

A section or specific page on the website.
For example, if citing the HCV Testing and Linkage to Care section:
AASLD-IDSA. HCV testing and linkage to care. Recommendations for testing, managing, and treating hepatitis C. https://www.hcvguidelines.org/full-report/hcv-testing-and-linkage-care. $$$Insert date accessed here$$$.

How to request permission to reprint or use content in the Guidance

Copyright Clearance Center can process your request for permissions to reprint or reuse the Hepatitis C Guidance content.

With copyright.com, you can quickly and easily secure the permissions you want.

Simply follow these steps to get started:

• Visit copyright.com and enter the title, “Recommendations for Testing, Managing, and Treating Hepatitis C” or CCC system ID: 451238344 and hit “Go”
• After finding the GUIDANCE, choose “Pay-Per-Use Options”
• Enter the publication year of the content you’d like to reuse
• Scroll down the list to find the type of reuse you want to request
• Select the corresponding bubble and click “Price & Order”
• Fill out any required information and follow the prompts to acquire the proper permissions to reuse the content that you’d like

For questions about using the service on copyright.com, please contact:
Copyright Clearance Center
222 Rosewood Drive
Danvers, MA 01923
Phone: +1-(978) 750-8400
Fax: +1-(978) 750-4470

Additional requests can be sent directly to info@copyright.com.

About Copyright Clearance Center
Copyright Clearance Center, the rights licensing expert, is a global rights broker for the world’s most sought-after books, journals, blogs, movies, and more.  Founded in 1978 as a not-for-profit organization, CCC provides smart solutions that simplify the access and licensing of content that lets businesses and academic institutions quickly get permission to share copyright-protected materials, while compensating publishers and creators for the use of their works. We make copyright work. For more information, visit www.copyright.com.

Notable changes are highlighted in yellow for approximately 1 month.

Retreatment Box (Summary). Recommendations for Patients in Whom Previous PEG/RBV Treatment Has Failed

For patients with genotype 1 HCV and prior PEG/RBV failure the treatment duration of PEG/RBV in the alternate regimen SMV/PEG/RBV has been corrected to 48 weeks; for patients with genotype 4 HCV and prior PEG/RBV failure, SOF +RBV x 24 weeks was corrected to be listed as an alternative regimen and SMV/ PEG/RBV was removed as an alternative; for patients with genotype 5 or 6 HCV the incorrect listing of SOF/RBV as an alternative regimen was removed.

For patients with prior PEG/RBV/HCV protease inhibitor failure, this portion of the box was reformatted for clarity and alternative regimens by IFN eligibility have been listed.

Retreatment of Persons in Whom Prior Therapy Has Failed

1, Genotype 1. The recommended regimen for prior failures of PEG/RBV/HCV protease inhibitor regimens was added for clarity; the alternative regimen; the alternative regimen (and supporting text) for IFN ineligible patients was added.

Unique Patient Populations: HIV/HCV Coinfection Summary

Tipranavir (as described in the text) was added to the table of not allowable with SOF use.

We are pleased to announce a new member to the HCV Guidance Panel: Hugo E. Vargas, MD, of the College of Medicine, Mayo Clinic.